Under the terms of the agreement, Lion TCR obtains worldwide non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return,
“We are thrilled to partner with Lion TCR to support the development of their TCR-T cell therapies for hepatocellular carcinoma and life-threatening viral infections,” said
Lion’s proprietary TCR-T cell therapy platform is supported by robust research, in collaboration with renowned laboratories, in the areas of autologous T cells and ’off-the-shelf’ technologies. The company’s TCR-T cell therapy harnesses the patient’s own immune system to fight against viral infections and cancers. The company is conducting ongoing clinical trials against hepatocellular carcinoma to evaluate the safety and efficacy of its TCR-T cells. Lion has engineered Hepatitis B virus (HBV)-specific T cells to recognize HBV-expressing tumor cells and achieve targeted killing, which is key as HBV is a major cause of hepatocellular carcinoma.
“At Lion TCR, we aspire to be the world’s leader in the field of mRNA-based TCR-T therapeutics through the technological advancement and development of adoptive T cell therapy products for cancers and cancer-causing infectious diseases,” said CEO,
MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically-validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Lion TCR is MaxCyte’s 24th strategic partnership overall, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments.
About
At
About
Lion TCR, a clinical stage biotech spun off from Singapore’s A*STAR, specializes in engineered T Cell Receptor (TCR) T cell therapies for infectious diseases and associated cancers, particularly HBV-related hepatocellular carcinoma (HCC). Lion TCR have secured FDA IND approval for a Phase 1b/2 trial — the world’s first FDA-approved international multi-center trial for its HBV TCR-T therapy (LioCyx-M004) against HCC. Additionally, LioCyx-M004 has received dual Fast Track and Orphan Drug Designations from the FDA. Lion TCR's groundbreaking approach involves utilizing mRNA to encode HBV-specific TCR in patients' T cells, enabling the targeting of HBV epitopes expressed in liver cancer cells. Positive clinical trial outcomes attest to its efficacy. Building on their mRNA technology and AI-enabled TCR discovery platforms, Lion TCR extends its focus to solid tumors, offering personalized cell therapy and 'off-the-shelf' solutions. This positions Lion TCR to develop a robust pipeline for diverse solid cancers and chronic viral diseases. Learn more at liontcr.com.
MaxCyte Contacts:
US IR Adviser
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
venes@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
Lion TCR Contacts:
2
#09-04
+65 68130738
Source:
2024 GlobeNewswire, Inc., source